Related
Endeavor Bio Raises $132.5 Million to Advance Pipeline of Transformational Medicines
Rare Daily Staff Endeavor BioMedicines raised $132.5 million in a series C financing, including the conversion of […]
Read moreFDA Grants Accelerated Approval to Day One’s Ojemda for Childhood Brain Tumor
Rare Daily Staff The U.S. Food and Drug Administration has granted accelerated approval to Day One Biopharmaceuticals’ […]
Read moreProfluent Releases AI-Created and Open-Source Gene Editor
Rare Daily Staff Profluent said it demonstrated the first successful precision editing of the human genome with […]
Read moreEC Grants Accelerated Approval to Travere and CSL Vifor’s Filspari for Rare Kidney Disease
Rare Daily Staff The European Commission granted accelerated approval to Travere Therapeutics and CSL Vifor’s Filspari for […]
Read moreFDA Approves Novartis’ Lutathera for Children with Rare Neuroendocrine Tumors
Rare Daily Staff The U.S. Food and Drug Administration approved Novartis’ radioligand therapy Lutathera for the treatment […]
Read moreSeamless Raises $25 Million in Seed Financing, Expands to U.S. to Advance Programmable Gene Editing Platform
Rare Daily Staff German biotech Seamless Therapeutics closed a $25 million in seed financing to support the […]
Read moreLifeArc Invests $50 Million to Launch Rare Disease Research Centers
Rare Daily Staff The UK charity LifeArc is investing $50 million (£40 million) to launch four new […]
Read moreGeneDx Partners with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
Rare Daily Staff GeneDx and Komodo Health have entered into a strategic partnership to increase access to […]
Read moreFDA Tells Abeona It Won’t Approve RDEB Cell Therapy without Additional CMC Information
Rare Daily Staff The U.S. Food and Drug Administration told Abeona Therapeutics that it would not approve […]
Read more